UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$21.6B |
| 2 |
Amazon
AMZN
|
+$13.7B |
| 3 |
NVIDIA
NVDA
|
+$3.87B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.89B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.4B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$22.7B |
| 2 |
Equinix
EQIX
|
+$857M |
| 3 |
Digital Realty Trust
DLR
|
+$655M |
| 4 |
NetEase
NTES
|
+$618M |
| 5 |
BNY
Bank of New York Mellon
BNY
|
+$609M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.9% |
| 2 | Financials | 13.9% |
| 3 | Consumer Discretionary | 11.31% |
| 4 | Healthcare | 10.7% |
| 5 | Communication Services | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
Amphastar Pharmaceuticals
AMPH
$916M
| $2.15M | ﹤0.01% |
93,652
+14,563
| +18% | +$361K |
|
2102
Root
ROOT
$798M
| $2.15M | ﹤0.01% |
16,781
+8,745
| +109% | +$1.18M |
|
|
ETWO
2103
DELISTED
E2open Parent Holdings
ETWO
| $2.15M | ﹤0.01% |
664,705
+166,580
| +33% | +$438K |
|
2104
Capitol Federal Financial
CFFN
$1.1B
| $2.15M | ﹤0.01% |
351,859
+118,287
| +51% | +$669K |
|
2105
Bloomin' Brands
BLMN
$938M
| $2.14M | ﹤0.01% |
248,101
+52,147
| +27% | +$419K |
|
2106
Tidewater
TDW
$4.12B
| $2.13M | ﹤0.01% |
46,130
+1,297
| +3% | +$52.5K |
|
2107
Transcat
TRNS
$871M
| $2.13M | ﹤0.01% |
24,752
+4,498
| +22% | +$368K |
|
|
RC
2108
Ready Capital
RC
$308M
| $2.13M | ﹤0.01% |
486,748
+44,316
| +10% | +$197K |
|
2109
InMode
INMD
$880M
| $2.12M | ﹤0.01% |
147,046
+28,334
| +24% | +$416K |
|
|
INVX
2110
Innovex International
INVX
$1.97B
| $2.12M | ﹤0.01% |
135,586
+37,361
| +38% | +$574K |
|
2111
Bausch Health
BHC
$2.34B
| $2.11M | ﹤0.01% |
317,268
-7,579
| -2% | -$38.9K |
|
2112
Metropolitan Bank Holding Corp
MCB
$1.15B
| $2.11M | ﹤0.01% |
30,142
+13,136
| +77% | +$813K |
|
|
GDEN
2113
DELISTED
Golden Entertainment
GDEN
| $2.11M | ﹤0.01% |
71,528
+10,141
| +17% | +$276K |
|
2114
Anavex Life Sciences
AVXL
$310M
| $2.1M | ﹤0.01% |
227,741
+129,107
| +131% | +$1.1M |
|
2115
Castle Biosciences
CSTL
$979M
| $2.1M | ﹤0.01% |
102,742
+34,711
| +51% | +$643K |
|
2116
Evolv Technologies
EVLV
$1.1B
| $2.09M | ﹤0.01% |
335,392
+143,551
| +75% | +$664K |
|
2117
MarineMax
HZO
$788M
| $2.09M | ﹤0.01% |
83,080
+34,570
| +71% | +$766K |
|
2118
HealthStream
HSTM
$840M
| $2.08M | ﹤0.01% |
75,351
+20,997
| +39% | +$621K |
|
2119
Kforce
KFRC
$1.06B
| $2.08M | ﹤0.01% |
50,506
+11,090
| +28% | +$465K |
|
|
UDMY
2120
DELISTED
Udemy
UDMY
| $2.07M | ﹤0.01% |
294,356
+89,040
| +43% | +$614K |
|
2121
Quanex
NX
$1.01B
| $2.07M | ﹤0.01% |
109,361
+33,134
| +43% | +$587K |
|
2122
ImmunityBio
IBRX
$8.1B
| $2.06M | ﹤0.01% |
781,800
+349,459
| +81% | +$940K |
|
|
VERV
2123
DELISTED
Verve Therapeutics
VERV
| $2.06M | ﹤0.01% |
183,610
+50,044
| +37% | +$285K |
|
2124
Enviri
NVRI
$620M
| $2.06M | ﹤0.01% |
237,016
+80,302
| +51% | +$588K |
|
2125
SunCoke Energy
SXC
$797M
| $2.06M | ﹤0.01% |
239,335
+82,138
| +52% | +$712K |
|
Similar funds
UBS AM's Q2 2025 Portfolio in Review
As of Q2 2025, UBS AM held 2,749 positions worth $494B, up 26% from $391B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
UBS AM deployed $54.3B of net new capital in Q2 2025, opening 106 new positions and adding to 2,036 existing holdings. Its largest new stake was Amrize Ltd: 12,343,881 shares worth $612M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Microsoft, an estimated $22.7B trimmed.
- UBS AM's largest Q2 2025 buy was Amrize Ltd: 12,343,881 shares worth $612M.
- UBS AM added most to Apple in Q2 2025, an estimated $21.6B increase.
- UBS AM's biggest Q2 2025 reduction was Microsoft, cutting an estimated $22.7B.
- UBS AM fully exited Discover Financial Services in Q2 2025, selling an estimated $356M.
- UBS AM's ten largest holdings make up 28% of its $494B portfolio in Q2 2025.
- UBS AM opened 106 new positions and closed 128 in Q2 2025.
- UBS AM's portfolio value rose 26% quarter-over-quarter to $494B.
Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.